Cities Changing Diabetes

Cities Changing Diabetes is a global program sponsored by Novo
Nordisk in partnership with University College London and Steno
Diabetes Center, in which nine cities around the world are learning
how to improve diabetes prevention, detection and care in their
communities. Urban areas have unique features and challenges, and this
program aims to map the problem, share solutions and drive action to fight the diabetes challenge.

Houston was selected due to its
challenging future with diabetes

The Cities Changing Diabetes program invested more than a year
researching the diabetes epidemic in Houston. A community-wide
assessment identified the populations most at risk for developing the
disease and developed profiles of those most at risk.

In Houston, Cities Changing Diabetes found fresh insights from
localized research

By establishing profiles of Houstonians, the Cities Changing Diabetes
program is able to think in new ways about people at risk for diabetes
and prediabetes.

Isolated Skeptics

Disconnected from community, lack trust in health care system

Financially-pressured caregivers

Caregiver responsibilities, long commutes

Concerned Seniors

Low health literacy, dealing with change and transition in neighborhood

Time-pressured Young Adults

Facing time pressure, peer influence on appearance and health decisions

Novo
Nordisk USA

Headquartered in Denmark, Novo Nordisk is a global healthcare
company with 95 years of innovation and leadership in diabetes care.
This heritage has given us experience and capabilities that also
enable us to help people defeat other serious chronic conditions: rare
bleeding disorders, growth hormone-related disorders, and obesity.

All personal information reported in relation
to a complaint or a side effect will be processed in accordance with
applicable data protection legislation. For avoidance of doubt, “data
protection legislation” means the law governing the Novo Nordisk
entity receiving the complaint or report, not the residence or
location of the individual data subject submitting the report or
complaint:

Your report is used solely for the scientific evaluation of
the medicine and product quality.

Side effects are filed in
our global safety database and the data is regularly analyzed for
overall patterns.

Novo Nordisk may share reported
complaints and side effects with health authorities as mandated by
law, regulation or as required by court order.

Novo Nordisk
will retain the data consistent with Novo Nordisk’s data retention
policies and as long as required by law.